MET and neoplasm: MET is overexpressed in PTC and associated with increased extrathyroidal extension rates, higher tumor stages, more frequent nodal metastases, a higher prevalence of BRAFV600E mutations, and an increased 10-year locoregional recurrence rate [12, 15–19].